80307-12-6

Usage

Uses

Used in Bioconjugation:
GMBS is used as a cross-linking reagent for bioconjugation, particularly for the attachment of proteins, peptides, and other biomolecules to each other or to solid supports. Its maleimide group reacts with thiol groups, while its amine reactive group can be used to modify amine-containing molecules.
Used in Enzyme Immunoassays:
GMBS is used as a heterobifunctional cross-linking reagent in enzyme immunoassays. Its amine and sulfhydryl reactivity make it useful for linking enzymes to antibodies or other molecules, improving the sensitivity and specificity of the assay.
Used in Drug Delivery Systems:
GMBS can be used in the development of drug delivery systems, where it can be employed to attach drug molecules to targeting ligands or nanoparticles, enhancing the delivery and efficacy of the therapeutic agents.
Used in Biosensor Development:
GMBS can be used in the fabrication of biosensors, where it can be employed to immobilize biological recognition elements, such as enzymes or antibodies, onto sensor surfaces, improving the performance and stability of the sensors.
Used in Protein Engineering:
GMBS can be used in protein engineering to introduce specific modifications or tags to proteins, enabling their detection, purification, or immobilization for various applications, such as affinity chromatography or surface plasmon resonance.
Used in Tissue Engineering:
GMBS can be used in tissue engineering to cross-link proteins or other biomolecules to scaffolds, promoting cell adhesion, growth, and tissue regeneration.
Used in Diagnostics:
GMBS can be used in the development of diagnostic tools, where it can be employed to attach signaling molecules or labels to antibodies or other recognition elements, improving the sensitivity and specificity of diagnostic assays.
Overall, GMBS is a versatile cross-linking reagent with a wide range of applications in various fields, including bioconjugation, enzyme immunoassays, drug delivery, biosensor development, protein engineering, tissue engineering, and diagnostics. Its unique combination of maleimide and amine reactive groups allows for the specific and efficient modification of a variety of biomolecules, making it a valuable tool in the development of new therapies, diagnostic tools, and research techniques.

InChI:InChI=1/C12H12N2O6/c15-8-3-4-9(16)13(8)7-1-2-12(19)20-14-10(17)5-6-11(14)18/h3-4H,1-2,5-7H2

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 57078-98-5 4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanoic acid 
• 116965-29-8 4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanoyl chloride 
• 15938-22-4 C₈H₁₁NO₅ 
• 108-31-6 maleic anhydride 
• 56-12-2 4-amino-n-butyric acid 

Downstream Products

• 1037794-15-2 C₆₄H₇₄ClN₁₁O₁₃ 
• 1037794-63-0 C₆₀H₇₂ClN₁₁O₁₃ 
• 1310812-56-6 (S)-2-(2-{4-[4-(2,5-dioxo-2,5-dihydro-(1H)-pyrrole-1-yl)butanamido]benzyl}-4,7-bis(carboxymethyl)-1,4,7-triazacylononane)acetic acid 

Relevant academic research and scientific papers

Synthesis of desmosine-BSA/KLH conjugates via Sonogashira/Negishi cross-coupling reactions

Desmosine is an elastin crosslinking amino acid that is expected to be a useful biomarker of diseases related to elastin degradation including chronic obstructive pulmonary disease (COPD). In this study, conjugates of desmosine and carrier proteins, such

Towards the development of a targeted albumin-binding radioligand: Synthesis, radiolabelling and preliminary in vivo studies

Introduction: The compound named 4-[10-(4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanamido)decyl]-11-[10-(β,D-glucopyranos-1-yl)-1-oxodecyl]-1,4,8,11-tetraazacyclotetradecane-1,8-diacetic acid is a newly synthesised molecule capable of binding in vivo to

CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS

Provided are conjugates of camptothecin analogs with a cell-binding molecule of formula (I), wherein R1, R2, R3, R4, R5, X, L, n, m, T and ----- are defined herein. It also provides methods of making the conjugates of camptothecin analogs to a cell-binding agent, as well as methods of using the conjugates in targeted treatment of cancer, infection, and immunological disorders.

A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS

Provided herein is the conjugation of an amanita toxin compound to a cell-binding molecule with branched linkers for having better targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of an amanita molecule to a cell-binding ligand, as well as methods of using the conjugate in targets treatment of cancer, infection and autoimmune disease.

A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS

Provided is a conjugation of cytotoxic drug to a cell-binding molecule with a side-chain linker. It provides side-chain linkage methods of making a conjugate of a cytotoxic molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and immunological disorders.

A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS

The present invention relates to the conjugation of a tubulysin analog compound to a cell-binding molecule with branched/side-chain linkers for having better delivery of the conjugate compound and targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of a tubulysin analog molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and autoimmune disease.

Synthesis N - maleic imide-based arylalkylic and its succinyl eater of method

The invention provides a method for synthesizing N-maleimidoalkyl acid and succinimido ester thereof, which comprises the following steps: (a) carrying out cyclization reaction on a compound disclosed as Formula (II) and phenyl 4-nitrotrifluoroacetate in an organic solvent in the presence of alkali to obtain N-maleimidoalkyl acid disclosed as Formula (III); and (b) reacting the N-maleimidoalkyl acid disclosed as Formula (III) and an acylation reagent in an organic solvent at reflux temperature to obtain an acyl chloride intermediate disclosed as (IV), reacting the acyl chloride intermediate disclosed as (IV) with N-hydroxy succinimide in an organic solvent in the presence of alkali to obtain the N-maleimidoalkyl acid succinimido ester disclosed as Formula (V). The method has the advantages of simple technique, high yield and high product purity, and is suitable for industrial production. The reaction route is disclosed in the specification.

Immobilised Biological Entities

There is described inter alia a medical device having a surface which comprises a coating layer, said coating layer being a biocompatible composition comprising an anti-coagulant entity capable of interacting with mammalian blood to prevent coagulation or

Azide-alkyne cycloaddition for universal post-synthetic modifications of nucleic acids and effective synthesis of bioactive nucleic acid conjugates

The regioselective post-synthetic modifications of nucleic acids are essential to studies of these molecules for science and applications. Here we report a facile universal approach by harnessing versatile phosphoramidation reactions to regioselectively incorporate alkynyl/azido groups into post-synthetic nucleic acids primed with phosphate at the 5′ termini. With and without the presence of copper, the modified nucleic acids were subjected to azide-alkyne cycloaddition to afford various nucleic acid conjugates including a peptide-oligonucleotide conjugate (POC) with high yield. The POC was inoculated with human A549 cells and demonstrated excellent cell-penetrating ability despite cell deformation caused by a small amount of residual copper chelated to the POC. The combination of phosphoramidation and azide-alkyne cycloaddition reactions thus provides a universal regioselective strategy to post-synthetically modify nucleic acids. This study also explicated the toxicity of residual copper in synthesized bioconjugates destined for biological systems. This journal is the Partner Organisations 2014.